ID: ALA499345

Max Phase: Preclinical

Molecular Formula: C19H15BrClN5

Molecular Weight: 428.72

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccccc3Cl)[nH]c2n1

Standard InChI:  InChI=1S/C19H15BrClN5/c20-12-5-3-6-13(9-12)23-17-15-10-14(24-18(15)26-19(22)25-17)8-11-4-1-2-7-16(11)21/h1-7,9-10H,8H2,(H4,22,23,24,25,26)

Standard InChI Key:  ISXTVMIMVFTRIL-UHFFFAOYSA-N

Associated Targets(Human)

EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT1 Tclin Vascular endothelial growth factor receptor 1 (6262 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDGFRB Tclin Platelet-derived growth factor receptor beta (5195 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A-431 (6446 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Gallus gallus (1187 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Igf1r Insulin-like growth factor 1 receptor (35 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Insr Insulin receptor (70 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 428.72Molecular Weight (Monoisotopic): 427.0199AlogP: 5.29#Rotatable Bonds: 4
Polar Surface Area: 79.62Molecular Species: NEUTRALHBA: 4HBD: 3
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 4#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.11CX Basic pKa: 7.60CX LogP: 5.63CX LogD: 5.22
Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.41Np Likeness Score: -1.26

References

1. Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Warnke LA..  (2008)  Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.,  16  (10): [PMID:18467105] [10.1016/j.bmc.2008.04.019]
2. Li R, Pourpak A, Morris SW..  (2009)  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.,  52  (16): [PMID:19610618] [10.1021/jm9002395]
3. Gangjee A, Zaware N, Raghavan S, Yang J, Thorpe JE, Ihnat MA..  (2012)  N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.,  20  (7): [PMID:22370340] [10.1016/j.bmc.2012.01.029]

Source